# Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection

> **NCT03788434** · PHASE2 · COMPLETED · sponsor: **Vedanta Biosciences, Inc.** · enrollment: 79 (actual)

## Conditions studied

- Clostridium Difficile Infection Recurrence
- Clostridium Difficile Infection
- Clostridium Difficile
- Clostridioides Difficile Infection Recurrence
- Clostridioides Difficile Infection
- Clostridioides Difficile
- CDI

## Interventions

- **DRUG:** VE303
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03788434
- **Lead sponsor:** Vedanta Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-08
- **Primary completion:** 2021-06-02
- **Final completion:** 2021-09-15
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2023-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03788434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03788434, "Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03788434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*